Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

@article{Seymour2010EffectsOA,
  title={Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.},
  author={John F Seymour and Pierre Fenaux and Lewis R. Silverman and Ghulam J. Mufti and Eva Hellstr{\"o}m-Lindberg and Valeria Santini and Alan F. List and Steven D Gore and Jay Backstrom and David Mckenzie and Charles L Beach},
  journal={Critical reviews in oncology/hematology},
  year={2010},
  volume={76 3},
  pages={
          218-27
        }
}
This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (≥ 75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial. Patients were randomized to AZA (75 mg/m(2)/daysubcutaneously × 7 days every 28 days) (n=38) or CCR (n=49) and had median ages of 78 and 77 years, respectively. AZA significantly improved OS vs CCR (HR: 0.48 [95%CI: 0… CONTINUE READING
Highly Cited
This paper has 60 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Treatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts

Mediterranean journal of hematology and infectious diseases • 2013
View 4 Excerpts
Highly Influenced

61 Citations

01020'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 61 citations based on the available data.

See our FAQ for additional information.